


Schedule of Events

IDSOG 2020 VIRTUAL ANNUAL MEETING

All times are in Eastern Standard Time

Time (EST)	Function
	Thursday, August 13
5:30pm-6:30pm	Plenary Debate: To Report or Not to Report: What to Do about Trichomonas Vaginalis <i>Maria Trent, MD, MPH, Johns Hopkins Medicine</i> <i>Okeoma Mmeje, MD, University of Michigan</i>
6:30pm-7:30pm	Networking
	Friday, August 14
10:15am-10:45am	Business Meeting
11:00am-11:45am	ISS 2: Presented by Cepheid Campfire Tales from the World of Vaginal Infections Christina Muzny, MD, University of Alabama at Birmingham Jack Sobel, MD, Wayne State University Paul Nyirjesy, MD, Jefferson University 
12:00pm-12:10pm	Opening Remarks, Presidential & Program Chair Welcome
12:10pm-12:40pm	Plenary Speaker I: Hepatitis C and Pregnancy – Staying Focused <i>Brenna Hughes MD, MSc, Duke University</i>
Scientific Session I	
12:40pm-12:45pm	Abstract 1: Chorioamnionitis: Are we following diagnostic guidelines? <i>Barbara Neuhoff, MD, Louisiana State University Health Science Center</i>
12:45pm-12:50pm	Abstract 2: Association of chorioamnionitis and patent ductus arteriosus in a national u.s. cohort <i>Celeste Green, MD, MPH, University of North Carolina at Chapel Hill</i>
12:50pm-12:55pm	Abstract 3: Implementing a penicillin allergy de-labelling service for the obstetric population <i>Bei Yuan Zhang, MSPH, University of British Columbia</i>
12:55pm-1:00pm	Abstract 4: Postpartum inpatient admissions for pyelonephritis in the United States associated with high rates of severe maternal morbidity <i>Kateena Addae-Konadu, MD, PhD, Duke University</i>
1:00pm- 1:05pm	Abstract 5: Influenza and pertussis transplacental antibody transfer in women with and without preeclampsia <i>Ai-ris Collier, MD, Beth Israel Deaconess Medical Center</i>
1:05pm-1:20pm	Q+A
1:20pm-1:30pm	Break

1:30pm-2:00pm	<p style="text-align: center;">Plenary Speaker II: Using Critical Race Approaches to Investigate Black-White Differences in Health <i>Kemi Doll, MD, MSCR, University of Washington</i></p>
Scientific Session II	
2:00pm-2:05pm	<p>Abstract 6: Associations between HIV, antiretroviral therapy, and preterm birth in the women's interagency HIV study, 1994-2018 <i>Kartik Venkatesh, MD, PhD, University of North Carolina at Chapel Hill</i></p>
2:05pm-2:10pm	<p>Abstract 7: HIV testing after the first antenatal care visit during pregnancy and breastfeeding: Results from the first five quarters in 22 pefpar countries, September 1, 2018 – December 31, 2019 <i>D. Heather Watts, MD, U.S Department of State</i></p>
2:10pm-2:15pm	<p>Abstract 8: Variation of CD4 count in pregnant women living with HIV <i>Michelle Byrns, BSc, MSc, Université de Montréal</i></p>
2:15pm-2:20pm	<p>Abstract 9: Trichomonas vaginalis infection and preterm birth among a high-risk obstetric cohort in Atlanta, Georgia <i>Marisa Young, MD, PhD, Emory University</i></p>
2:20pm-2:25pm	<p>Abstract 10: An evaluation of the performance characteristics of the World Health Organization's syndromic diagnosis for c. trachomatis and n. gonorrhoeae infections among high risk women in mombasa, Kenya <i>Gregory Zane, BS, University of Washington</i></p>
2:25pm-2:40pm	Q+A
2:40pm-2:50pm	Break
Scientific Session III	
2:50pm-2:55pm	<p>Abstract 11: Effect of bacterial vaginosis on fecundability among HIV-negative Kenyan women planning pregnancies <i>Erica Lokken, MS, PhD, University of Washington</i></p>
2:55pm-3:00pm	<p>Abstract 12: In vitro activity of ibrexafungerp in pH 7.0 and pH 4.5 testing environments against 187 fluconazole-susceptible and -resistant candida species from vulvovaginal candidiasis patients. <i>Jack Sobel, MD, Wayne State University School of Medicine</i></p>
3:00pm-3:05pm	<p>Abstract 13: Oral ibrexafungerp efficacy and safety in the treatment of vulvovaginal candidiasis: A phase 3, randomized, blinded, study vs. placebo (VANISH-303) <i>Jane Schwebke, MD, University of Alabama at Birmingham</i></p>
3:05pm-3:10pm	<p>Abstract 14: Pattern of anti-fungal resistance among vulvovaginal candida species <i>Andrea Boyd-Tressler, PhD, The Cleveland Clinic Foundation</i></p>
3:10pm-3:15pm	<p>Abstract 15: A phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind study to evaluate the effectiveness and safety of a single oral dose of 2 grams of secnidazole for the treatment of trichomoniasis in women <i>Christina Muzny, MD, MSPH, University of Alabama at Birmingham</i></p>
3:15pm-3:30pm	Q+A
3:30pm-4:30pm	Virtual Networking
Saturday, August 15	
11:00am-11:45am	<p style="text-align: center;">ISS 3: Presented by Scynexis Current Challenges and Advancements in the Treatment of Vulvovaginal Candidiasis <i>Jack Sobel, MD, Wayne State University</i></p> <p style="text-align: center;"></p>
12:00pm-12:10pm	Opening Remarks, Presidential & Program Chair Welcome

12:10pm-12:40pm	<p style="text-align: center;">Plenary Speaker III: The promise and challenge of developing live biotherapeutics to prevent bacterial vaginosis and its sequelae <i>Anke Hemmerling, MD, PHD, MPH, University of California San Francisco</i></p>
Scientific Session IV	
12:40pm-12:45pm	<p>Abstract 16: Loss of function of nitric oxide reductase associated with neisseria gonorrhoeae infection in women <i>Tatum Mortimer, PhD, Harvard School of Public Health</i></p>
12:45pm-12:50pm	<p>Abstract 17: Macrophage production of matrix metalloproteases in the setting of chorioamnionitis <i>Erin Vraga, BS, Vanderbilt University School of Medicine</i></p>
12:50pm-12:55pm	<p>Abstract 18: Lactobacillus iners growth inhibition by cystine uptake inhibitors is a target for shifting cervicovaginal microbiota towards lactobacillus crispatus-dominant communities <i>Seth Bloom, MD, PhD, Massachusetts General Hospital</i></p>
12:55pm-1:00pm	<p>Abstract 19: Characterization of meconium-associated microbiota by cpn60-based microbiome profiling underscores the need for robust negative controls in the study of low microbial biomass samples <i>Scott Dos Santos, MSc, University of Saskatchewan</i></p>
1:00pm- 1:05pm	<p>Abstract 20: Metagenomic next generation sequencing analysis of vaginal microbiome composition in patients with bacterial vaginosis treated with lactin-v (Lactobacillus crispatus CTV-05) versus placebo <i>Gloria Castaneda, BS, Chan Zuckerberg Biohub</i></p>
1:05pm-1:20pm	Q+A
1:20pm-1:30pm	Break
1:30pm-2:00pm	<p style="text-align: center;">Plenary Speaker IV: COVID-19 Pandemic: Lessons Learned from a Large Obstetric Service in NYC. <i>Cynthia Gyamfi-Bannerman, MD, Columbia University</i></p>
Scientific Session V	
2:00pm-2:05pm	<p>Abstract 21: Late-season influenza: Don't let your guard down! <i>Alice Darling, BA, Duke University</i></p>
2:05pm-2:10pm	<p>Abstract 22: Assessing influenza vaccination behaviors among medically underserved obstetric patients <i>Emily Goggins, MD, MPH, Emory University School of Medicine</i></p>
2:10pm-2:15pm	<p>Abstract 23: Canadian surveillance of COVID-19 in pregnancy: Epidemiology and maternal and infant outcomes <i>Elisabeth McClymont, PHD, University of British Columbia</i></p>
2:15pm-2:20pm	<p>Abstract 24: Health disparities among pregnant women with sars-cov-2 infection at a university medical center in northern California <i>Iroque Iqbinosa, MD, Stanford University School of Medicine</i></p>
2:20pm-2:40pm	Q+A
2:40pm-2:50pm	Break
Scientific Session VI	
2:50pm-2:55pm	<p>Abstract 25: Perspectives of women receiving treatment for hepatitis c virus during pregnancy <i>Yasaswi Kislovskiy, MD, Magee Women's Hospital of UPMC</i></p>
2:55pm-3:00pm	<p>Abstract 26: The inadequacies of cytomegalovirus screening <i>Andy Wang, BS, University of Central Florida College of Medicine</i></p>
3:00pm-3:05pm	<p>Abstract 27: Chagas disease screening using point of care testing in an at-risk obstetric population <i>Lindsey Zamora, MD, MPH, Vanderbilt University Medical Center</i></p>

3:05pm-3:10pm	Abstract 28: <u>Use of fertility awareness methods as a safer conception strategy for women in HIV serodiscordant relationships</u> <i>Yasaman Zia, MPH, University of Washington</i>
3:10pm-3:15pm	Abstract 29: <u>Positive participant experiences with smart-phone based enhanced visualization with acetic acid for cervical cancer screening in mysore, India</u> <i>Sasha Herbst de Cortina, BA, University of California Irvine Medical Center</i>
3:15pm-3:30pm	Q+A

POSTER PRESENTATIONS

Poster #	Name	Abstract Title
1	LaMani Adkins, BS	Expedited partner therapy in school-based health centers: The right choice for the right patient
2	Sarah Bell, MD	Using thinprep® pap smear samples to evaluate sexually transmitted infection screening practices
3	Paige K. Bradley, BS	A qualitative comparison of society guidelines for syphilis screening in pregnancy
4	Barbara Van der Pol, MPH, PHD	Testing for three common sexually transmitted infections with a single FDA-cleared amplified molecular assay
5	Elizabeth H. Byrne, MSc	Inflammatory pathways within specific mucosal cell populations shed light on microbiome-associated inflammation in the female genital tract mucosa
6	Rachel Cevigney, BS	Adjustable algorithmic tool for assessing the effectiveness of maternal respiratory syncytial virus (RSV) vaccination on infant mortality in developing countries
7	Amanda M. Craig, MD	Listeria in pregnancy: What are the maternal outcomes?
8	Hannah Cunningham, MSc	The impact of anemia on infectious and obstetric outcomes of women with pyelonephritis
9	Jodie Dionne-Odom, MD, MSPH	Secondary infertility and bacterial sexually transmitted infections in Cameroon, Africa
10	Samantha Corey Do, MD	Comparison of lactate and procalcitonin levels in pregnant women with vs without intraamniotic infection during the peripartum period: The serum biomarkers of infection in labor evaluation (SMILE)
11	Yevgenia Fomina, MD	Evaluating the effect of mandatory prenatal syphilis screening laws on primary and secondary syphilis among women over time
12	Keonte J. Graves, MS	Identification of differentially expressed genes in metronidazole-resistant trichomonas vaginalis isolates
13	Elana Jaffe, BA	"Coronavirus has changed everything": experiences of pregnancy and birth among women impacted by the COVID-19 pandemic
14	Andrea K. Knittel, MD, PhD	The role of relationships in decision-making about pre-exposure prophylaxis (PrEP) for HIV among women who have experienced incarceration
15	Gweneth Bratton Lazenby, MD	Trends in chlamydia trachomatis and neisseria gonorrhoeae prevalence in pregnant women, South Carolina, 2008-2018.
16	Charlotte B. McCarley, MD	Outcomes following drug-use associated infection (DUA) protocol among pregnant patients
17	Monica K. Neuman, MD	Examination of HPV knowledge and desire to vaccinate in the immediate postpartum period
18	Sara Jannele Pauk, MD	Vaginitis 101: An online, self-directed vulvovaginal disorders curriculum for the obstetrics and gynecology resident
19	Renee Christine Reimer, MSc	Bacteremia in pregnant and postpartum women: Bacterial epidemiology, antibiotic use and neonatal outcomes
20	Michelle C Sabo, MD, PhD	Analysis of the association between vaginal washing and changes in vaginal microbiota using broad range polymerase chain reaction with 16S rRNA gene amplicon sequencing
21	Leah M. Savitsky, MD	Attitudes toward measles vaccination and vaccine hesitancy among pregnant women in Washington state
22	Meryl Megumi Sperling, MA, MD	Recurrent preterm birth in the infection pathway
23	Meryl Megumi Sperling, MA, MD	Risk of recurrent clinical chorioamnionitis in California
24	Anne West Honart, MD, Other	Gestational weight gain and neonatal outcomes by HIV status in an urban Zambian cohort
25	Jeffrey Man Hay Wong, MD	Establishing obstetrics-specific metrics and interventions for antimicrobial stewardship
26	Hailey Harris, BS	Cohorting prenatal care during the COVID-19 pandemic